Health
Semaglutide Shows Promise in Treating Serious Liver Condition, New Study Finds
A widely used ingredient in popular weight-loss drugs has shown promising results in treating a progressive liver condition for which no medications are currently approved in the European Union, according to a major new study published in the New England Journal of Medicine.
The clinical trial, funded by Danish pharmaceutical giant Novo Nordisk, found that semaglutide – the active compound in the blockbuster drugs Ozempic and Wegovy – significantly improved outcomes for patients suffering from metabolic dysfunction-associated steatohepatitis (MASH). The disease, which causes fat accumulation, inflammation, and scarring in the liver, is associated with obesity, type 2 diabetes, and high blood pressure and can progress to cirrhosis if left untreated.
The 72-week trial involved 800 participants with MASH and moderate to advanced liver fibrosis. Patients who received weekly injections of semaglutide showed notable improvements, with 33 percent experiencing reductions in both liver inflammation and scarring, compared to just 16 percent in the placebo group. Separately, 63 percent saw a decrease in liver inflammation, and 37 percent showed improved scarring. The placebo group showed improvements of 34 percent and 22 percent, respectively.
Participants taking semaglutide also lost an average of 10.5 percent of their body weight, reinforcing the drug’s potential dual benefit in treating both liver disease and obesity-related complications.
Professor Debbie Shawcross, a liver specialist at King’s College London and vice secretary general of the European Association for the Study of the Liver, called the findings “hugely exciting,” but cautioned that semaglutide alone may not be responsible for all the improvements. Participants across both treatment arms received lifestyle counseling and support in managing related health conditions, suggesting that behavior changes also played a significant role.
“This is important as any therapy that is licensed for MASH with moderate to severe fibrosis must be used in conjunction with lifestyle interventions,” Shawcross noted.
While semaglutide showed promise, some patients reported gastrointestinal side effects, including nausea, vomiting, and diarrhea. Around 2.6 percent of those on the drug withdrew from the study due to adverse effects.
Novo Nordisk, which announced the trial’s topline results in late 2024, has stated it plans to seek regulatory approval for semaglutide as a MASH treatment in both the EU and US by mid-2025. If approved, it would become the first such therapy available in Europe.
The move comes as the EU is also reviewing other experimental treatments for MASH, including resmetirom, which was approved in the US last year after showing positive results in reducing liver scarring.
While Shawcross said it is “too early to call” semaglutide a game-changer, she emphasized its potential if used alongside comprehensive lifestyle programs. However, she warned that many patients taking weight-loss drugs do not make lasting changes, raising concerns about the long-term impact once the medication is stopped.
Health
WHO Warns of Sharp Rise in Mental Health Conditions Among Europe’s Youth
A growing number of children and teenagers across Europe are experiencing mental health conditions, with global health officials warning that support systems are failing to keep pace with the surge. A new analysis released by the World Health Organization (WHO) outlines the scale of the challenge and calls for urgent action across the region.
According to the report, one in seven Europeans under the age of 20 are living with a mental health condition — a rise of about one-third over the past 15 years. The findings show clear gender disparities, with girls facing greater vulnerability. Among girls aged 15 to 19, one in four report having a mental health condition, making them the most affected group.
The report also highlights striking differences between countries. Teenagers in the Faroe Islands, Iceland and Denmark ranked among the highest for mental wellbeing, while those in Ukraine, Cyprus and Poland were placed at the lower end of the scale. The data reflects both long-term trends and the impact of recent crises.
Concerns about youth mental health have intensified in recent years, driven by a combination of social isolation, the effects of the COVID-19 pandemic, geopolitical tensions and growing economic pressures. Experts say these factors have created an environment in which young people are increasingly exposed to stress and uncertainty.
Access to professional support remains one of the region’s biggest obstacles. The WHO report notes that about one-quarter of European countries do not have community-based mental health services for young people. In addition, one in five countries lack dedicated mental health policies, leaving many children and teenagers without structured pathways to receive help.
“This report is a wake-up call,” said Dr. João Breda, who works on patient safety and healthcare quality at the WHO. “Every child and young person has the right to mental health support and high-quality care.”
The findings mark the first time the WHO has compiled extensive data on child and youth mental health across its European region, which includes 53 countries in Europe and Central Asia. The report stresses the need for stronger in-person care, noting rising concerns about young people turning to digital tools for emotional support. The document raises alarms about cases in which reliance on artificial intelligence chatbots, including ChatGPT, has led to harmful outcomes.
The WHO is urging governments to strengthen their mental health frameworks by increasing investment, expanding services and updating programmes to better reflect the needs of children and adolescents.
“By acting now, countries can build resilient systems that help the next generations thrive,” Breda said.
Health
Poliovirus Detected in Hamburg Wastewater, Raising Public Health Alerts
Health authorities in Germany have discovered traces of the poliovirus in sewage from Hamburg, highlighting a persistent health threat decades after Europe was declared polio-free. The finding has prompted renewed calls for enhanced disease monitoring and vaccination coverage.
Germany has not reported any confirmed cases of poliomyelitis, a highly contagious disease that primarily affects young children and can invade the nervous system, sometimes causing paralysis. The poliovirus detected in Hamburg’s wastewater is genetically similar to a strain last identified in Afghanistan, one of only two countries where polio remains endemic.
The European Centre for Disease Prevention and Control (ECDC) described the detection as “unusual, but not unexpected.” Germany’s last known locally transmitted polio case occurred in 1990, and the continent was officially declared polio-free in 2002. However, health officials caution that imported cases remain possible, particularly among populations with low vaccination coverage.
The World Health Organization (WHO) emphasized that the discovery underscores the ongoing risk: “Until polio is eradicated everywhere, all countries remain at risk of importation of the virus and potential re-infection.” Poliovirus can appear in sewage when individuals shed the virus in their stool. This does not necessarily indicate illness, as it can also result from people receiving the oral polio vaccine, which contains a weakened live virus.
Last year, similar detections in Germany, Poland, and Spain prompted health authorities to urge countries to strengthen surveillance systems and vaccination campaigns to protect populations from potential outbreaks. Across the European Union, vaccination coverage among one-year-olds ranged from 79 percent in Romania to 99 percent in Hungary and Luxembourg, according to WHO data. Experts note that gaps may persist at the local level, leaving some communities vulnerable to transmission.
Despite the presence of the virus in sewage, the ECDC stressed that the overall risk to the European population remains “very low.” Health authorities are using the findings to monitor trends and reinforce vaccination messaging, particularly in areas where immunization rates fall below recommended levels.
Germany’s recent detection serves as a reminder that polio, although rare in Europe, has not been fully eliminated globally. Public health officials continue to advocate for robust immunization programs, vigilant disease surveillance, and rapid response plans to prevent the virus from spreading should a case arise.
The Hamburg wastewater discovery has renewed focus on the importance of vaccination and monitoring, reinforcing global efforts to ensure that polio remains under control until it is eradicated worldwide.
Health
Scientists Explore New Frontiers in Autoimmune Disease Research as Cases Rise Worldwide
Scientists are still investigating potential causes and treatments for autoimmune conditions. Here’s what to know. Autoimmune diseases, which occur when the body’s defense system mistakenly attacks its own cells, now affect tens of millions of people globally. These conditions can strike nearly any part of the body and are most common among women, though men and children are not exempt. Rates have been climbing for years, raising urgent questions about how the immune system goes awry and how to better diagnose and treat these illnesses.
Researchers say progress in understanding the immune system is opening doors to new therapies that may go beyond controlling symptoms. “This is probably the most exciting time that we’ve ever had to be in autoimmunity,” said Dr Amit Saxena, a rheumatologist at NYU Langone Health in the United States. His optimism reflects a growing scientific push to reprogramme faulty immune responses rather than only suppress them.
Scientists have pinpointed a potential driver of the global rise in colon and rectal cancers among young people: ultra-processed foods. Women who ate the most ultra-processed foods had a higher risk of developing polyps that can lead to cancer compared with women who ate the least. The finding adds urgency to research into immune-related disorders, many of which appear to be influenced by environmental triggers.
More than 100 autoimmune diseases have been identified. Rheumatoid arthritis and psoriatic arthritis inflame joints. Sjögren’s disease is known for dry eyes and mouth. Myositis and myasthenia gravis weaken muscles, while lupus can attack organs ranging from the kidneys to the heart. Symptoms often ebb and flow unpredictably, with patients experiencing long periods of stability before suddenly facing a flare.
Diagnosing these conditions is notoriously difficult. Early signs are often vague, overlap with other illnesses, or appear sporadically. Doctors may order blood tests to search for misplaced antibodies, yet many patients spend years seeking answers from multiple specialists. Efforts to speed diagnoses are underway, including updated guidance for detecting multiple sclerosis.
Scientists are also studying how the immune system becomes confused. Normally, it distinguishes foreign threats from the body’s own tissues. When that tolerance breaks down, chronic disease can develop. Genetics can increase vulnerability, but usually an external trigger — infection, smoking, pollutants — is needed to set the process in motion. New evidence links the Epstein-Barr virus not only to multiple sclerosis but also to lupus, offering fresh insight into how hidden viral infections may spark long-term immune disruption.
Women face the highest risk of autoimmune disease, possibly due to hormonal influences or differences linked to the X chromosome. Some conditions, however, overwhelmingly affect men. VEXAS syndrome, discovered in 2020, typically strikes men over 50 with severe symptoms that include breathing problems and blood clots.
Treating autoimmune diseases remains complex. The global market for therapies exceeds $100 billion (€87 billion) annually, yet many patients still navigate trial-and-error treatment plans. While high-dose steroids and broad immune-suppressing drugs were once the main options, newer treatments now target specific molecules. The most promising new approach involves CAR-T therapy — originally developed for cancer — which wipes out malfunctioning immune cells and allows healthier ones to grow back. Early trials show potential benefits for lupus, myositis, and other conditions.
Scientists hope that continued research will bring earlier detection, better tools to prevent disease onset, and therapies that address root causes rather than symptoms.
-
Entertainment1 year agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business1 year agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business1 year agoRecent Developments in Small Business Taxes
-
Home Improvement12 months agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics1 year agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Business1 year agoCarrectly: Revolutionizing Car Care in Chicago
-
Business1 year agoSaudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Sports1 year agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
